Considerations for treatment duration in responders to immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the time was incurable, little attention was initially pa...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Immunother Cancer
Asıl Yazarlar: Marron, Thomas U, Ryan, Aideen E, Reddy, Sangeetha M, Kaczanowska, Sabina, Younis, Rania H, Thakkar, Dipti, Zhang, Jiajia, Bartkowiak, Todd, Howard, Rachel, Anderson, Kristin G, Olson, Daniel, Naqash, Abdul Rafeh, Patel, Ravi B, Sachdev, Esha, Rodriguez-Ruiz, Maria E, Sheffer, Michal, Church, Sarah, Fuhrman, Christopher, Overacre-Delgoffe, Abigail, Nguyen, Rosa, Florou, Vaia, Thaxton, Jessica E, Aggen, David H, Guerriero, Jennifer L
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2021
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7929825/
https://ncbi.nlm.nih.gov/pubmed/33653801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001901
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller